Our Approach

Accent’s approach integrates novel target space with the most successful approach to therapeutic intervention in the history of medicine: small, synthetic molecules. We are focusing on inhibitory small molecule drugs (SMDs) for their:

  • Extreme flexibility in design due to limitless diversity of structure and associated characteristics
  • Ease of analysis, aiding feedback in the development process
  • Dosing simplicity (oral dosing is commonplace for small molecule drugs)
  • Ease and cost-efficiency of manufacturing

While to date there have been relatively few inhibitors of RMPs reported, analogs for related protein families have already been described. These include small molecule inhibitors with favorable pharmacological properties, consistent with acceptable safety profiles, good oral bioavailability and pharmacokinetic characteristics that allow for convenient dosing schedules. Accent is undertaking the systematic chemical biology and drug discovery efforts required to characterize and target compelling RNA modifications as new approaches to precision cancer therapeutics.

Multi-parametric lead optimization

Multi-parametric lead optimization

The Accent team applies a multi-parametric approach to lead optimization to rapidly create clinic-ready molecules as investigational new drugs.

The Accent team is uniquely qualified to practice SMD discovery and development in the area of RMP inhibitors, building on a track record of success in delivering novel SMDs to the clinic. Among the executive team, scientific advisory board and board of directors, the Accent team has previously delivered more than 200 SMDs to the clinic and, collectively, have contributed to more than 40 approved drugs that are in clinical use today.

At Accent, we are combining cutting-edge approaches to target identification with a robust chemical biology platform and more traditional drug discovery approaches. This approach allows us to identify and prioritize the most critical RMP targets for specific human cancer indications and to swiftly match these targets with novel small molecule inhibitors that serve as powerful starting points for our drug optimization efforts. In partnership with trusted contract research organizations, we are building a model that encourages a diversity of approaches and can respond quickly to identified opportunities.